Why Small-Cap Pharma Stocks Are Beating Large Caps?
Small-cap pharmaceutical stocks have significantly outperformed their large-cap peers over the past year, with investors increasingly rewarding companies that have lower exposure to commoditised US generics and a stronger presence in niche, high-margin segments.
Among the small-cap names, Bliss GVS Pharma has surged 362% over the past year, while Ind-Swift Laboratories, Sakar Healthcare, Shilpa Medicare and Kwality Pharmaceuticals have jumped 281%, 217%, 149% and 282%, respectively.
In comparison, large-cap pharma stocks have delivered more moderate returns. Sun Pharmaceutical Industries share price gained 14%, Divis Laboratories rose 58%, Torrent Pharmaceuticals advanced 36%, while Zydus Lifesciences gained 12%. Cipla declined 10% during the period.
